Potassium para-aminobenzoate and liver function test findings

Area of Science:

• Rheumatology
• Hepatology
• Pharmacology

Background:

• Concerns exist regarding the potential hepatotoxicity of potassium para-aminobenzoate (Potaba).
• Scleroderma patients are a key population for evaluating drug safety due to potential comorbidities and treatment regimens.

Purpose of the Study:

• To investigate the risk of hepatotoxicity associated with potassium para-aminobenzoate (Potaba) therapy in scleroderma patients.
• To determine if Potaba causes acute hepatic hypersensitivity reactions or long-term liver damage.

Main Methods:

• Retrospective analysis of clinical and laboratory hepatic findings.
• Comparison of 390 scleroderma patients, with 274 treated with Potaba and 116 untreated controls.

Main Results:

• No cases of acute hepatic hypersensitivity reactions attributed to Potaba were identified.
• Hepatic test abnormalities occurred randomly and more frequently in the untreated group.
• No evidence indicated that long-term Potaba therapy is hepatotoxic.

Conclusions:

• Acute hepatic reactions to potassium para-aminobenzoate appear to be uncommon or rare in scleroderma patients.
• The study suggests Potaba is not a significant cause of liver injury in this patient cohort.